Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · broad
The model's full reasoning — Q4 2023 call → NOWe need to evaluate the transcript for two gates. Gate 1: Is there a positive current development that Q&A adds concrete detail about beyond prepared remarks? Gate 2: Is that development based on broad granular demand base? Let's analyze the call. The company is Premier, Inc. They discuss fiscal 2023 results. Positive developments: They mention growth in Performance Services, adjacent markets (applied sciences, Contigo Health, clinical decision support). They mention a clinical trial win with a top 10 pharma company. They mention Remitra, AI-enabled supply chain. They mention GPO retention, etc. In Q&A, analysts ask about various things. Let's see if any positive development gets more concrete detail in Q&A. Key positive: Applied sciences business, clinical trial win. In prepared remarks, Mike says: "our applied sciences business signed an end-to-end clinical trial with one of the top 10 largest pharmaceutical companies in the world." That's a specific win. In Q&A, Richard Close asks about applied sciences and clinical trial win. Mike gives more detail: "we're able to sort of flip the funnel... using our AI capability and looking at the unstructured data... inclusion and exclusion criteria before we actually select the site and the physician investigators... we have been doing some things from a Phase IV study standpoint, where we're creating synthetic control arm... allows for us not to have the whole placebo kind of comparators... more efficient and incredibly accurate given that we have the data." That is additional detail about the offering, but is it about the specific win? It describes the capabilities. It doesn't give more specifics about the actual trial, like which pharma, size, timeline, etc. It's more about the approach. Is that "concrete operating detail"? It's about the methodology, not the specific deal. The question was "maybe a little bit more detail on the clinical trial win that you highlighted and really the opportunity for growth in that adjacent market would be helpful." Mike's answer describes the offering and the opportunity, but not the specific win's details. He says "we have been doing some things from a Phase IV study standpoint" - that's general. He doesn't add specifics about the signed trial. So that might not be additive in terms of the specific development. Another positive: Contigo Health.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FTAI | Fortress Transportation and Infrastructu | Q2 2024 | 2024-07-24 | A |
| FYBR | Frontier Communications Parent, Inc. | Q1 2024 | 2024-05-03 | B |
| TOL | Toll Brothers, Inc. | Q1 2024 | 2024-02-21 | A |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | A |
| ZWS | Zurn Elkay Water Solutions Corporation | Q4 2023 | 2024-02-07 | B |
| TMUS | T-Mobile US, Inc. | Q4 2023 | 2024-01-25 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| WEAV | Weave Communications, Inc. | Q3 2023 | 2023-11-01 | B+ |
| MAC | The Macerich Company | Q3 2023 | 2023-10-31 | D |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| SURG | SurgePays, Inc. | Q2 2023 | 2023-08-12 | D |
| EVLV | Evolv Technologies Holdings, Inc. | Q2 2023 | 2023-08-10 | B+ |
| TREX | Trex Company, Inc. | Q2 2023 | 2023-07-31 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| NOW | ServiceNow, Inc. | Q2 2023 | 2023-07-26 | A |
| UTHR | United Therapeutics Corporation | Q1 2023 | 2023-05-03 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| MGM | MGM Resorts International | Q1 2023 | 2023-05-01 | A |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| PAYX | Paychex, Inc. | Q3 2023 | 2023-03-29 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | A |
| SHW | The Sherwin-Williams Company | Q2 2022 | 2022-07-27 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| APLE | Apple Hospitality REIT, Inc. | Q4 2021 | 2022-02-23 | A |
| DV | DoubleVerify Holdings, Inc. | Q3 2021 | 2021-11-11 | B |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| AMH | American Homes 4 Rent | Q3 2021 | 2021-11-05 | B+ |
| BIGC | BigCommerce Holdings, Inc. | Q3 2021 | 2021-11-04 | B+ |
| SPSC | SPS Commerce, Inc. | Q3 2021 | 2021-10-28 | A |
| INBK | First Internet Bancorp | Q3 2021 | 2021-10-21 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| SNY | Sanofi | Q3 2018 | 2018-10-31 | B+ |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | A |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SNDR | Schneider National, Inc. | Q1 2018 | 2018-04-26 | A |
| ROKU | Roku, Inc. | Q4 2017 | 2018-02-21 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | A |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| FIVN | Five9, Inc. | Q4 2016 | 2017-02-17 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| SEM | Select Medical Holdings Corporation | Q1 2016 | 2016-05-06 | C+ |
| PLNT | Planet Fitness, Inc. | Q4 2015 | 2016-03-03 | A |
| BECN | Beacon Roofing Supply, Inc. | Q1 2016 | 2016-02-05 | B |
APLE · Q4 2021 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a clear positive current development in the company's hotel portfolio recovery, particularly around Q1 2022 demand trends and operational metrics. In prepared remarks, Justin Knight and Liz Perkins highlight overall RevPAR improvement, leisure strength, and business travel recovery, but without granular February specifics.
MKC · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES NO (Gate 2 fails because the Frank’s/French’s growth is repeatedly tied to specific large retailers, national accounts, and one major customer whose shelf-reset decisions and promotional activity are named or implied as key drivers; the transcript never establishes a broad, granular base of many independent counterparties whose small decisions are widening adoption.
GAIA · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a positive current development in organic subscriber growth and the member referral program. Prepared remarks note organic contributions over 40% and reduced marketing spend. Q&A provides additive details: specific referral mechanics (7-day free watch), ambassador program vs.